Evidence map›Paper›PMID 35480391›Full record

ArticleFrontiers in chemistry2022

Hydrazones and Thiosemicarbazones Targeting Protein-Protein-Interactions of SARS-CoV-2 Papain-like Protease.

Wiebke Ewert, Sebastian Günther, Francesca Miglioli, Sven Falke, Patrick Y A Reinke, Stephan Niebling, Christian Günther, Huijong Han, Vasundara Srinivasan, Hévila Brognaro and 8 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 2 countries.

Wiebke EwertCenter for Free-Electron Laser Science CFEL, Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany.
Sebastian GüntherCenter for Free-Electron Laser Science CFEL, Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany.
Francesca MiglioliDepartment of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy.
Sven FalkeCenter for Free-Electron Laser Science CFEL, Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany.
Patrick Y A ReinkeCenter for Free-Electron Laser Science CFEL, Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany.
Stephan NieblingEuropean Molecular Biology Laboratory Hamburg, DESY, Hamburg, Germany.
Christian GüntherEuropean Molecular Biology Laboratory Hamburg, DESY, Hamburg, Germany.
Huijong HanEuropean XFEL GmbH, Schenefeld, Germany.
Vasundara SrinivasanInstitute of Biochemistry and Molecular Biology, Laboratory for Structural Biology of Infection and Inflammation, Department of Chemistry, University Hamburg, Hamburg, Germany.
Hévila BrognaroInstitute of Biochemistry and Molecular Biology, Laboratory for Structural Biology of Infection and Inflammation, Department of Chemistry, University Hamburg, Hamburg, Germany.
Julia LieskeCenter for Free-Electron Laser Science CFEL, Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany.
Kristina LorenzenEuropean XFEL GmbH, Schenefeld, Germany.
Maria M Garcia-AlaiEuropean Molecular Biology Laboratory Hamburg, DESY, Hamburg, Germany.
Christian BetzelInstitute of Biochemistry and Molecular Biology, Laboratory for Structural Biology of Infection and Inflammation, Department of Chemistry, University Hamburg, Hamburg, Germany.
Mauro CarcelliDepartment of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy.
Winfried HinrichsInstitute of Biochemistry, University Greifswald, Greifswald, Germany.
Dominga RogolinoDepartment of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy.
Alke MeentsCenter for Free-Electron Laser Science CFEL, Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany.
Deutsches Elektronen-Synchrotron DESY · DEEuropean Molecular Biology Laboratory · DEUniversity of Parma · ITCenter for Free-Electron Laser Science · DEEuropean X-Ray Free-Electron Laser · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The papain-like protease (PLpro) of SARS-CoV-2 is essential for viral propagation and, additionally, dysregulation of the host innate immune system. Using a library of 40 potential metal-chelating compounds we performed an X-ray crystallographic screening against PLpro. As outcome we identified six compounds binding to the target protein. Here we describe the interaction of one hydrazone (H1) and five thiosemicarbazone (T1-T5) compounds with the two distinct natural substrate binding sites of PLpro for ubiquitin and ISG15. H1 binds to a polar groove at the S1 binding site by forming several hydrogen bonds with PLpro. T1-T5 bind into a deep pocket close to the polyubiquitin and ISG15 binding site S2. Their interactions are mainly mediated by multiple hydrogen bonds and further hydrophobic interactions. In particular compound H1 interferes with natural substrate binding by sterical hindrance and induces conformational changes in protein residues involved in substrate binding, while compounds T1-T5 could have a more indirect effect. Fluorescence based enzyme activity assay and complementary thermal stability analysis reveal only weak inhibition properties in the high micromolar range thereby indicating the need for compound optimization. Nevertheless, the unique binding properties involving strong hydrogen bonding and the various options for structural optimization make the compounds ideal lead structures. In combination with the inexpensive and undemanding synthesis, the reported hydrazone and thiosemicarbazones represent an attractive scaffold for further structure-based development of novel PLpro inhibitors by interrupting protein-protein interactions at the S1 and S2 site.

Indexed as

COVID-19deubiquitinationdrug discoverylead compoundspapain-like proteaseSARS-CoV-2x-ray crystallography

Identifiers

PMID35480391
PMCPMC9038201
OpenAlexW4223575819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.